定量18F-FDG PET/CT模型预测NSCLC新辅助免疫化疗后病理完全缓解:与RECIST 1.1和PERCIST的比较
本研究回顾性纳入2020年1月至2023年12月接受新辅助免疫化疗的可切除非小细胞肺癌患者36例,其中19例(52.8%)达到病理完全缓解,基于ΔTLR%和第二次扫描的SULpeak构建定量预测模型,AUC为0.975,灵敏度100%、特异度94.1%,优于RECIST 1.1和PERCIST,并用2024年1月至9月外部队列8例进行验证。
要点
- ΔTLR%与第二次扫描SULpeak是新辅助免疫化疗后pCR的独立预测因子。
- 定量模型AUC 0.975,灵敏度100%、特异度94.1%,优于RECIST 1.1和PERCIST。
- 外部验证8例确认模型准确性,但需更大队列进一步验证。
核心结论
- 本研究提示18F-FDG PET/CT,特别是ΔTLR%和第二次扫描的SULpeak,是可切除NSCLC接受新辅助免疫化疗后pCR的可靠预测指标,定量预测模型优于RECIST 1.1和PERCIST。
- 作者认为这些发现凸显该模型的潜在临床效用,但需更大队列进一步验证以确认其稳健性和普适性。
研究设计与样本
- 回顾性研究,纳入2020年1月至2023年12月接受新辅助免疫化疗的可切除NSCLC患者36例用于模型开发,另用2024年1月至9月外部队列8例进行验证。
- 纳入患者均有治疗前(18F-FDG PET/CT scan-1)和术前(18F-FDG PET/CT scan-2)两次扫描,收集PET/CT参数、临床特征和随访数据,采用逻辑回归识别独立预测因子并构建预测模型。
- 以术后病理结果作为pCR的金标准,并将模型预测性能与RECIST 1.1和PERCIST标准进行比较。
主要发现
- 模型开发队列36例中19例(52.8%)达到pCR。
- ΔTLR%(两次扫描间肿瘤与肝脏摄取比值百分比变化)和第二次扫描的SULpeak为显著预测因子。
- 预测模型AUC为0.975,灵敏度100%,特异度94.1%。
- RECIST 1.1灵敏度10.5%、特异度100%;PERCIST灵敏度73.7%、特异度94.1%。
- 外部验证8例确认模型准确性。
关键数值与推荐
- 预测模型:AUC 0.975,灵敏度100%,特异度94.1%。
- RECIST 1.1:灵敏度10.5%,特异度100%。
- PERCIST:灵敏度73.7%,特异度94.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需更大队列进一步验证以确认模型的稳健性和普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the predictive value of 18F-FDG PET/CT for pathological complete response (pCR) after neoadjuvant immunochemotherapy in resectable non-small cell lung cancer (NSCLC) and develop a quantitative pCR prediction model. We compared the model's performance with RECIST 1.1 and PERCIST. METHOD: A retrospective review was conducted on patients with resectable NSCLC who received neoadjuvant immunochemotherapy from January 2020 to December 2023. Patients with both pre-treatment (18F-FDG PET/CT scan-1) and preoperative scans (18F-FDG PET/CT scan-2) were included. 18F-FDG PET/CT parameters, clinical characteristics, and follow-up data were collected. Logistic regression was used to identify independent predictors and construct the prediction model. The model's predictive performance was compared with RECIST 1.1 and PERCIST criteria. The model was validated with an external cohort from January to September 2024. Postoperative pathological results serve as the gold standard for pCR. RESULTS: 36 patients were included for model development, with 19 (52.8%) achieving pCR. ΔTLR% (percentage change between two scans in tumor-to-liver ratio) and SULpeak from scan-2 were significant predictors. The developed prediction model demonstrated outstanding performance with an area under the curve (AUC) of 0.975, 100% sensitivity, and 94.1% specificity. In comparison, RECIST 1.1 showed poor sensitivity (10.5%) but high specificity (100%), while PERCIST had moderate sensitivity (73.7%) and specificity (94.1%). Validation with 8 patients confirmed the model's accuracy. CONCLUSIONS: This study suggests that 18F-FDG PET/CT, specifically the ΔTLR% and SULpeak from scan-2, is a reliable predictor of pCR in resectable NSCLC undergoing neoadjuvant immunochemotherapy. The quantitative prediction model outperforms both RECIST 1.1 and PERCIST. These findings highlight the potential clinical utility of this model, although further validation with larger cohorts is required to confirm its robustness and generalizability.
引用
- Deng Y, Zhang X, Hu F, et al. Quantitative 18F-FDG PET/CT Model for predicting pathological complete response to neoadjuvant immunochemotherapy in NSCLC: comparison with RECIST 1.1 and PERCIST. Eur J Nucl Med Mol Imaging. 2025. PMID: 40418330. doi:10.1007/s00259-025-07342-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。